Survivorship: fatigue, version 1.2014

Journal of the National Comprehensive Cancer Network: JNCCN (Impact Factor: 4.18). 06/2014; 12(6):876-87.
Source: PubMed


Many cancer survivors report that fatigue is a disruptive symptom even after treatment ends. Persistent cancer-related fatigue affects quality of life, because individuals become too tired to fully participate in the roles and activities that make life meaningful. Identification and management of fatigue remains an unmet need for many cancer survivors. This section of the NCCN Guidelines for Survivorship provides screening, evaluation, and management recommendations for fatigue in survivors. Management includes education and counseling, physical activity, psychosocial interventions, and pharmacologic treatments.

22 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fatigue is a distressing and persistent symptom that can be produced by gynecological cancer or by its treatment.•The development of mechanism-driven fatigue interventions through translational and clinical research is necessary to achieve greater symptom control.•Knowledge of mechanisms producing fatigue and standardized methods for fatigue measurement and management in routine oncology care are lacking.
    Gynecologic Oncology 10/2014; 136(3). DOI:10.1016/j.ygyno.2014.10.013 · 3.77 Impact Factor
  • D Qu · Z Zhang · X Yu · J Zhao · F Qiu · J Huang ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer-related fatigue (CRF) is a common symptom affecting 60-90% of cancer survivors, and effective management for CRF is not yet available. Recently, an increasing number of trials examining the use of psychotropic drugs for the treatment of CRF have been performed, but these trials have yielded inconsistent results. Therefore, we conducted a meta-analysis aimed at assessing the effect and safety of psychotropic drugs for the management of CRF. Ten eligible trials of the psychotropic drugs methylphenidate and modafinil in a total of 1582 participants treated for CRF were subjected to statistical analyses. A meta-analysis of seven of these studies indicated that methylphenidate was superior to placebo for the treatment of CRF. Another meta-analysis of three studies evaluating modafinil found that this drug was no better than placebo. Adverse events were similar between both methylphenidate and modafinil and the placebo groups. Our meta-analysis indicated that the treatment of CRF with methylphenidate appears to be effective, whereas modafinil provides no benefit. These results of this analysis warrant further trials to confirm the efficacy and safety of psychotropic drugs for the treatment of CRF.
    European Journal of Cancer Care 10/2015; DOI:10.1111/ecc.12397 · 1.56 Impact Factor

Similar Publications